TSS
BCTX

Two Sigma Securities’s Briacell Therapeutics BCTX Stock Holding History

Two Sigma Securities’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-92
Closed -$60.2K – 2657
2022
Q4 		$60.2K Buy
+92
New +$77.9K ﹤0.01% 2133

Other funds holding BCTX

LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
KJHP
K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
CWP
Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Two Sigma Securities's BCTX Position: Q1 2023 in Review

Two Sigma Securities sold out of Briacell Therapeutics (BCTX) in Q1 2023, closing a stake of 92 shares — an estimated $60.2K sold.

Two Sigma Securities first reported a position in BCTX in Q4 2022 and held it in 1 quarter. The position peaked at $60.2K in Q4 2022. 17 funds tracked by Wall St. Rank hold BCTX as of Q1 2023.

  • Two Sigma Securities reported no remaining Briacell Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Two Sigma Securities sold 92 Briacell Therapeutics shares in Q1 2023, an estimated $60.2K.
  • Two Sigma Securities first reported a position in Briacell Therapeutics in Q4 2022 and held it in 1 quarter.
  • Two Sigma Securities's Briacell Therapeutics position peaked at $60.2K in Q4 2022.
  • 17 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2023.

Based on Two Sigma Securities's 13F filing for Q1 2023, filed 15 May 2023.